OpenAI vs Google DeepMind
Side-by-side trajectory, velocity, and editorial themes.
Codex everywhere, sovereign-AI deals, and a math proof — OpenAI is pushing on all fronts at once.
OpenAI is operating on three simultaneous fronts: Codex distribution into enterprise (Dell on-premise, Databricks, Ramp case studies, role-specific playbooks for data science and ops), country-level deployment deals (Singapore, Malta, the broader Education for Countries program), and frontier research signaling (a model disproving a long-standing discrete-geometry conjecture). Underpinning all of it is GPT-5.5, which is now the named model behind the agent and Codex workloads. Trust infrastructure — Content Credentials, SynthID, a public verification tool — is being shipped alongside the expansion.
The product surface is shifting from a single chat product to a distribution layer: Codex is being placed inside customer infrastructure (Dell hybrid, Databricks notebooks) and inside countries (national ChatGPT Plus access, training programs). The customer-story cadence around Codex suggests OpenAI is moving from 'try the API' to documented vertical use cases — code review, RCA briefs, leadership memos — that map to org-chart roles rather than developer personas. Provenance work and the research milestone are doing different jobs in parallel: one defends against regulatory pressure, the other resets the ceiling on what 'frontier' means.
Expect more country-level rollouts on the Malta/Singapore template, and Codex packaging that targets specific corporate functions (finance, legal, ops) with pre-baked deliverables rather than raw model access. The next visible move is likely a Codex SKU with deeper enterprise data-residency controls — Dell paved the surface, the SKU follows.
DeepMind is repositioning Gemini as the substrate for scientific research, not just consumer AI.
DeepMind's recent output is dominated by Co-Scientist case studies and the formal launch of a 'Gemini for Science' suite, with applied research wins clustered around biology — aging, ALS, liver disease, infectious disease triggers. A second strand expands consumer-facing tools (Project Genie + Street View) for Google AI Ultra subscribers and pushes on content provenance. National partnership announcements (Singapore) round out the geopolitical surface.
The center of gravity is shifting from frontier model releases to vertical applications, particularly in life sciences. Co-Scientist appears to be moving from internal project to a packaged offering institutions can collaborate on. Consumer features and content authenticity work continue in parallel but feel secondary to the science push.
Expect a formal Co-Scientist productization announcement with institutional access tiers within the next quarter, and additional 'Gemini for X' verticals (likely materials science or drug discovery) to follow the science framing.
See more alternatives to OpenAI →
See more alternatives to Google DeepMind →